Fuller & Thaler Asset Management Inc. Makes New Investment in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Fuller & Thaler Asset Management Inc. bought a new position in Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 163,385 shares of the biopharmaceutical company’s stock, valued at approximately $2,662,000. Fuller & Thaler Asset Management Inc. owned about 0.55% of Intercept Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the business. Lazard Asset Management LLC purchased a new position in Intercept Pharmaceuticals in the fourth quarter worth about $691,000. Bank of America Corp DE raised its stake in shares of Intercept Pharmaceuticals by 81.4% in the fourth quarter. Bank of America Corp DE now owns 379,060 shares of the biopharmaceutical company’s stock worth $6,174,000 after buying an additional 170,116 shares during the period. Integral Health Asset Management LLC bought a new position in shares of Intercept Pharmaceuticals in the fourth quarter worth about $1,222,000. Jackson Creek Investment Advisors LLC bought a new position in shares of Intercept Pharmaceuticals in the fourth quarter worth about $970,000. Finally, Dupont Capital Management Corp raised its stake in shares of Intercept Pharmaceuticals by 47.0% in the fourth quarter. Dupont Capital Management Corp now owns 30,780 shares of the biopharmaceutical company’s stock worth $501,000 after buying an additional 9,846 shares during the period. 83.44% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:ICPT opened at $18.01 on Tuesday. Intercept Pharmaceuticals, Inc. has a 1 year low of $11.60 and a 1 year high of $22.36. The stock’s 50 day simple moving average is $16.29 and its two-hundred day simple moving average is $16.43. The company has a market cap of $535.13 million, a price-to-earnings ratio of -8.00 and a beta of 1.27.

Intercept Pharmaceuticals (NASDAQ:ICPTGet Rating) last released its quarterly earnings data on Wednesday, March 2nd. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.03. The firm had revenue of $92.40 million during the quarter, compared to the consensus estimate of $91.89 million. During the same period in the previous year, the firm earned ($1.58) EPS. On average, equities research analysts expect that Intercept Pharmaceuticals, Inc. will post -2.35 EPS for the current fiscal year.

Several research analysts have recently commented on ICPT shares. Needham & Company LLC decreased their price objective on Intercept Pharmaceuticals from $30.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, March 3rd. StockNews.com started coverage on Intercept Pharmaceuticals in a research note on Thursday, March 31st. They issued a “buy” rating on the stock. Royal Bank of Canada decreased their price objective on Intercept Pharmaceuticals from $22.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Thursday, March 3rd. SVB Leerink decreased their target price on Intercept Pharmaceuticals from $30.00 to $27.00 and set a “market perform” rating on the stock in a research note on Thursday, March 3rd. Finally, Canaccord Genuity Group decreased their target price on Intercept Pharmaceuticals from $31.00 to $29.00 and set a “hold” rating on the stock in a research note on Tuesday, March 8th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $26.57.

About Intercept Pharmaceuticals (Get Rating)

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults.

Featured Stories

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals, Inc. (NASDAQ:ICPTGet Rating).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.